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Abstract 
Background: The risk prediction of pregnancy‑associated plasma protein‑A (PAPP‑A) for future cardiovascular (CV) 
events post acute coronary syndrome (ACS) in patients with type‑2 diabetes mellitus (T2DM) was investigated in 
comparison to other risk factors.
Methods: PAPP‑A was measured at hospital admission in 320 consecutive ACS patients (136 with T2DM and 184 
without). All patients were followed for 2 years for occurrence of CV death, non‑fatal MI or stroke. Effect of PAPP‑A on 
the CV event risk was estimated using Cox regression models. Receiver operating characteristics (ROC) curves were 
generated to demonstrate the sensitivity and specificity of PAPP‑A in predicting CV events.
Results: ACS patients with T2DM had higher PAPP‑A (19.29 ± 16.36 vs. 13.29 ± 13.90 ng/ml, p < 0.001) and higher 
rate of CV events 2 years post ACS (27.2 vs. 13.6%, p = 0.002) than those without. Higher levels of PAPP‑A were 
significantly associated with increased risk of CV events during 2‑year follow‑up [HR = 2.97 for 1 SD increase in 
 log10(PAPP‑A), 95% CI 2.11–4.18, p < 0.001] in T2DM and (HR = 3.16, 95% CI 2.27–4.39, p < 0.001) in non‑T2DM. Among 
patients with T2DM, PAPP‑A showed a larger area under the curve (AUC 0.79) that was significantly more predictive 
than hsCRP (AUC 0.64), eGFR (AUC 0.66) and LVEF < 50% (AUC 0.52); predictive ability did not improve significantly by 
including those factors into the model.
Conclusions: Patients with T2DM had higher levels of PAPP‑A and increased risk of CV events. Elevated PAPP‑A com‑
pared to other risk factors was a stronger predictor for future CV events 2 years post ACS in patients with T2DM.
Trial registration ISRCTN10805074. Registered on 20 January 2017, retrospectively registered.
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Background
Patients with type-2 diabetes mellitus (T2DM) are known 
to suffer worse outcomes post-acute coronary syndrome 
(ACS) [1, 2]. Identification of factors that can improve 
the risk prediction of cardiovascular outcomes in T2DM 
remains clinically challenging [3]. Previous research 
has found that pregnancy-associated plasma protein-
A (PAPP-A), a high molecular weight and zinc-binding 
metalloproteinase, is an important regulatory protein in 
cell proliferation and the development of atherosclerosis 
and can degrade the proteins that maintain the integrity 
of the protective fibrous cap of atherosclerotic plaques 
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[4, 5]. PAPP-A, originally found in pregnant women, is 
produced by syncytiotrophoblast cells in a heterotetra-
meric complex (500  kDa) [6], but also by osteoblasts, 
fibroblasts, endothelial cells, vascular smooth muscle 
cells [4, 7, 8] and by monocytes and macrophages [9, 10] 
in a homodimer (400  kDa) with proteolytic activity [6]. 
Previous studies have demonstrated that PAPP-A is a 
potentially important biomarker of plaque instability and 
inflammation in patients with ACS [11, 12]. PAPP-A has 
been identified in vulnerable coronary plaques but not 
found in stable plaques [13] and higher PAPP-A levels are 
associated with higher 3-vessel thin-cap fibroatheroma 
(TCFA) burden in patients with coronary artery disease 
[14]. Furthermore, subjects with T2DM appeared to have 
higher levels of PAPP-A than age-matched controls [15, 
16]. However, whether the increased levels of PAPP-A 
in T2DM can better predict future CV events post ACS 
had not been studied. Therefore, we prospectively inves-
tigated the risk prediction of serum PAPP-A concen-
trations for future CV events in ACS patients with and 
without T2DM in comparison to other risk factors.
Methods
Study population
As shown in Fig.  1, a total of 420 patients with sus-
pected ACS including ST-elevation myocardial infarction 
(STEMI), non-ST-elevation MI (Non-STEMI) and unsta-
ble angina (UA) were admitted to CCU and 1 of 4 cardiac 
wards at the Beijing Friendship Hospital Cardiovascular 
Center between June and November 2012. Of these 420 
patients, 344 were confirmed with ACS [17, 18]. Three 
hundred twenty subjects completed the study and were 
included in the final analysis.
Informed consent was obtained from all subjects prior 
to any study related procedures or measurements. The 
study protocol and procedures received approval from 
the Beijing Friendship Hospital Institutional Review 
Board and were performed to conform to the Declaration 
of Helsinki.
T2DM was diagnosed based on fasting plasma glu-
cose ≥7.0 mmol/l, or 2-h plasma glucose ≥11.1 mmol/l, 
or HbA1C  ≥6.5%, or receiving treatment for diabetes 
[19].
Laboratory analysis
Routine laboratory tests on lipids, glucose level, Hs-CRP, 
hepatic and renal functions were performed using the 
standardized methods at the Beijing Friendship Hospi-
tal Laboratory. Cardiac troponin I (cTnI) was detected 
by electro-chemiluminescence technology for quanti-
tative measurement (3rd generation TnI, Elecsys 2010, 
Roche, Mannheim, Germany). The lower detection limit 
is 0.01 µg/l with a recommended diagnostic threshold of 
0.03  µg/l for MI. N-terminal B-type natriuretic peptide 
(NT-proBNP) was measured using electrochemilumi-
nescence immunoassays performed on a Roche Elecsys 
2010 automated platform (Roche Diagnostics, Burgess 
Hill, UK). Additional blood samples were collected with 
EDTA preparation at the time of routine laboratory tests 
[20] and were stored at −80 °C.
Total serum PAPP-A was measured before heparin 
administration and blinded to subject characteristics, 
Fig. 1 Study subject enrollment and completion
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laboratory results and clinical course using the ultra-
sensitive enzyme-linked immunosorbent assay (ELISA) 
method with kits manufactured by DRG Instruments 
GmBH (Germany). This method with sensitivity of 
0.023  ng/ml is specially designed to detect low concen-
trations of circulating enzyme that is associated with pos-
sible plaque rupture [21].
Echocardiograms
Echocardiography was performed routinely at hospital 
admission. Digital echocardiograms were analyzed on the 
EchoPAC workstation (Philips IE Elite). Left ventricular 
end-diastolic and -systolic volumes were obtained using 
Simpson’s method of discs in the apical 4- and 2-cham-
ber views as recommended by the American Society of 
Echocardiography [22]. Left ventricular ejection fraction 
(LVEF) was calculated using left ventricular volumes and 
the formula: [(end-diastolic volume  −  end-systolic vol-
ume)/end-diastolic volume] × 100%.
CV outcomes
Events including CV death, nonfatal MI or stroke were 
identified during the initial hospitalization for ACS, and 
at 6  month intervals for up to 24  months per the study 
follow-up schedule. Each event was evaluated and con-
firmed with medical records. Events possibly related 
to ACS treatment procedures (PCI or CABG) were 
excluded. A composite of CV death, nonfatal MI or 
stroke was the pre-defined study primary endpoint.
Statistical analysis
Comparisons of clinical characteristics and laboratory 
measurements between subjects with and without T2DM 
were performed using unpaired t-tests for continuous 
variables and Chi square tests for categorical variables. 
Kaplan–Meier curves and Cox regression for the com-
posite CV event were generated to compare the event-
free survival difference between subjects with or without 
T2DM.
Cox regression analysis was used to determine the fac-
tors that were associated with the risk of subsequent CV 
events post-ACS. Four models were considered for the 
effect of PAPP-A on the risk of events: (1) model with 
PAPP-A value, (2) model with  log10(PAPP-A), (3) model 
with linear spline for PAPP-A (with a knot at the 60th 
percentile, PAPPA  =  13.16  ng/ml) and (4) categorical 
model (lower quartile  ≤8.46  ng/ml, 2nd and 3rd quar-
tiles combined  >8.46 and  <17.3  ng/ml and 4th quar-
tile  ≥17.4  ng/ml). Among the four candidate models 
 log10(PAPP-A) was selected for the largest Cox & Snell 
pseudo  R2 [23].
The effect of PAPP-A on the risk of CV events was also 
tested in multivariate models that adjusted for covariates 
including: diabetes status, age, gender, LVEF (%), HbA1C, 
Troponin I and hsCRP. Due to the limited number of 
events (37 events in T2DM subjects and 24 in non-
T2DM subjects) only a single covariate was adjusted for 
at a time. A covariate was considered as confounding if 
the adjustment for the covariate changed the hazard ratio 
(HR) for PAPPA-A by at least 10%.
Receiver operating characteristics (ROC) curves were 
generated to demonstrate the ability to predict CV 
events. Area under the ROC curve (AUCs) was calculated 
for single predictor and selected multivariate models 
(the latter based on logistic regression). The multivari-
ate logistic regression models used all predictors that had 
AUC > 0.6. To determine whether PAPP-A had a differ-
ent ability to predict CV events compared to other single 
factors or to the multivariate model, we used DeLong’s 
test to compare pairs of correlated ROC curves [24]. We 
would like to point out that this test is perhaps unfair to 
PAPP-A when it is being compared to the multivariate 
model because PAPP-A is part of the multivariate model 
and DeLong’s test does not account for the number of 
other predictors in the multivariate model. Confidence 
intervals for AUC were calculated with the non-paramet-
ric bootstrap with 2000 replicates.
All tests were two tailed and p < 0.05 was considered 
statistically significant. All statistical analyses were per-




Overall, among the 320 subjects, 68% were male, mean 
age was 65  years (range 27–90  years), 31% were diag-
nosed with STEMI, 26% with non-ST elevation MI and 
43% with unstable angina. Of the 320 subjects, 168 (53%) 
received PCI, 11 (3%) received CABG in addition to 
medical management, and 141 (44%) were treated only 
with medical therapy during hospitalization. The pro-
portion of medical management during hospitalization 
and at discharge was ASA (97%),  P2Y12 inhibitor (72%), 
statin (92%), β-blocker (75%) and angiotensin converting 
enzyme inhibitor/angiotensin-receptor blocker (72%). 
There was no significant difference in treatment dur-
ing hospitalization between subjects with and without 
T2DM (Table 1).
As shown in Table  1, 136 subjects with T2DM, com-
pared to 184 without, were significantly more likely 
to be female (39 vs. 27%, p =  0.021), to have hyperlipi-
demia (61 vs. 49%, p = 0.042) and lower LVEF (56 ± 12 
vs. 60 ± 12%, p = 0.001). Subjects with T2DM had sig-
nificantly higher PAPP-A concentrations (19.3  ±  16.4 
vs. 13.3  ±  13.9  ng/ml, p  <  0.001) and hsCRP levels 
(8.4  ±  5.9 vs. 6.5  ±  5.7  ng/ml, p  <  0.001) than those 
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Table 1 Baseline clinical characteristics and laboratory assessment
Values are mean ± SD or n (%)
T2DM type-2 diabetes mellitus, BP blood pressure, MI myocardial infarction, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary 
artery bypass graft, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin-receptor blocker, LVEF left ventricular ejection fraction, LDL-C low density 
lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, AST aspartate aminotransferase, ALT alanine aminotransferase, hsCRP high sensitive C-reactive 
protein, PAPP-A pregnancy-associated plasma protein-A, NT-proBNP N-terminal B-type natriuretic peptide, eGFR estimated glomerular filtration rate
All (n = 320) T2DM (−) (n = 184) T2DM (+) (n = 136) p value
Age, years 65 ± 12 64 ± 12 66 ± 11 0.108
Male, n (%) 218 (68) 135 (73) 83 (61) 0.021
Physical sign
 Body mass index, kg/m2 25.4 ± 3.5 25.3 ± 3.4 25.5 ± 3.6 0.661
 Systolic BP, mmHg 129 ± 21 128 ± 19 132 ± 24 0.090
 Diastolic BP, mmHg 74 ± 12 74 ± 12 74 ± 12 0.078
Cardiovascular risk factors
 Current smoking 117 (37) 73 (40) 44 (32) 0.179
 History of smoking 146 (46) 91 (50) 55 (40) 0.114
 Hypertension 205 (64) 112 (61) 93 (68) 0.195
 Hyperlipidemia 174 (54) 91 (50) 83 (61) 0.042
 Previous CAD 72 (23) 44 (24) 28 (21) 0.502
 Previous MI 39 (12) 21 (11) 18 (13) 0.730
 Previous PCI or CABG 59 (18) 34 (19) 25 (18) 1.000
 Previous stroke 43 (13) 24 (13) 19 (14) 0.869
ACS diagnosis and treatment
 ST elevation MI 101 (31) 58 (31) 43 (31) 0.985
 Non‑ST elevation MI 82 (26) 47 (26) 35 (26) 0.969
 Unstable angina 137 (43) 79 (43) 58 (43) 0.959
 PCI 168 (53) 94 (51) 74 (54) 0.556
 CABG 11 (3) 3 (2) 8 (6) 0.080
 Medical therapy
  ASA 309 (97) 180 (98) 129 (95) 0.257
  Y2P12 inhibitor 231 (72) 132 (72) 99 (73) 0.835
  Statin 293 (92) 170 (92) 123 (90) 0.535
  β‑Blocker 240 (75) 133 (72) 107 (79) 0.192
  ACEI/ARBs 229 (72) 129 (70) 100 (74) 0.503
LVEF, % 59 ± 12 60 ± 12 56 ± 12 0.001
Laboratory assessment
 Fasting glucose, mmol/l 6.6 ± 3.0 5.5 ± 1.7 8.2 ± 3.5 <0.001
 HbA1C,  % 6.5 ± 1.5 5.7 ± 0.5 7.6 ± 1.8 <0.001
 Total cholesterol, mmol/l 4.3 ± 1.0 4.2 ± 1.0 4.4 ± 1.1 0.322
 Triglycerides, mmol/l 1.85 ± 1.21 1.65 ± 1.04 2.13 ± 1.37 <0.001
 LDL‑C, mmol/l 2.24 ± 0.59 2.23 ± 0.59 2.24 ± 0.59 0.937
 HDL‑C, mmol/l 0.93 ± 0.22 0.94 ± 0.21 0.92 ± 0.23 0.229
 AST, U/L 68.2 ± 94.6 67.1 ± 83.9 69.7 ± 107.7 0.333
 ALT, U/L 28.2 ± 24.9 27.4 ± 22.8 29.2 ± 27.5 0.607
 Creatinine µmol/l 102.3 ± 117.4 101.5 ± 118.5 103.4 ± 116.6 0.961
 hsCRP, ng/ml 7.3 ± 5.8 6.5 ± 5.7 8.4 ± 5.9 <0.001
 PAPP‑A, ng/ml 15.8 ± 15.3 13.3 ± 13.9 19.3 ± 16.4 <0.001
 CK‑MB, ng/ml 14.8 ± 37.1 17.9 ± 44.7 10.6 ± 22.8 0.713
 Troponin I, ng/ml 3.3 ± 8.4 3.2 ± 8.3 3.5 ± 8.4 0.474
 NT‑proBNP, pg/ml 2352.5 ± 5746.6 1745.8 ± 4603.3 3173.4 ± 6937.3 0.128
 eGFR, ml/min 1.73 m2 81.3 ± 23.4 82.7 ± 21.6 79.4 ± 25.6 0.217
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without. As expected, subjects with T2DM showed sig-
nificantly higher levels of fasting blood glucose (8.2 ± 3.5 
vs. 5.5 ±  1.7 mmol/l, p < 0.001) and HbA1C (7.6 ±  1.8 
vs. 5.7  ±  0.5%, p  <  0.001). The T2DM group also had 
higher triglycerides (2.13 ± 1.37 vs. 1.65 ± 1.04 mmol/l, 
p < 0.001), but no significant difference was seen in the 
levels of total cholesterol, low-density lipoprotein cho-
lesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), creatinine, CK-MB, cTnI, NT-
proBNP or eGFR.
CV outcomes
During the 24  months of follow-up, 4.4, 9.0 and 7.8% 
were confirmed for CV death, nonfatal MI and stroke, 
respectively. Overall, there were 62 patients (37 with 
T2DM and 25 without T2DM) with a CV event. The 
overall 2-year event free survival rate for the composite 
CV outcome was 80.9% (95% CI 76.7, 85.4). As shown 
in Fig.  2, the 2-year event free survival rate in subjects 
with T2DM was 72.8% (95% CI 65.7–80.7), which was, 
not surprisingly, significantly lower than that in subjects 
without T2DM 86.9% (95% CI 82.2–92.0) (p = 0.002, Cox 
regression).
Unadjusted and adjusted association between PAPP‑A 
and CV outcomes
The univariate Cox regression analysis identified that ele-
vated PAPP-A was significantly associated with increased 
occurrence of CV events in all subjects and subjects with 
and without T2DM as shown in Table  2. HR per 1 SD 
increase in  log10(PAPP-A) was 2.97 (95% CI 2.11–4.18) 
in subjects with T2DM, 3.16 (95% CI 2.27–4.39) in those 
without T2DM and 3.10 (95% CI 2.48–3.87) in all sub-
jects, all p  <  0.001, respectively. In addition, older age, 
hypertension, lower LVEF, higher HbA1C, lower eGFR, 
higher cTnT and higher hsCRP were also significantly 
associated with increased risk of CV events in the uni-
variate analysis.
After the adjustment for age, gender, LVEF, HbA1C, 
cTnI or hsCRP (a single adjustment variable at a time), 
the effect of PAPP-A on CV events in all subjects and 
subjects with and without T2DM changed by <10% sug-
gesting that these factors do not confound the relation-
ship between PAPP-A and the CV event risk (Table 3).
Predictive effects of PAPP‑A on CV outcomes
Areas under the ROC curves (AUC) for PAPP-A, age, 
LVEF, eGFR, hsCRP and the combination of all these 
predictors (from a multivariate logistic regression includ-
ing all predictors) are shown in Fig. 3 and Table 4. Spe-
cifically, among subjects with T2DM (Fig.  3a), PAPP-A 
showed AUC of 0.79 (95% CI 0.70–0.87) which was sig-
nificantly larger than LVEF (AUC 0.52; 95% CI 0.40–0.64; 
p < 0.001), eGFR (AUC 0.66; 95% CI 0.56–0.77; p = 0.03) 
and hsCRP (AUC 0.64; 95% CI 0.52–0.76; p  =  0.01). 
Similar results were also seen in those without T2DM 
(Fig. 3b) and in all subjects (Fig. 3c).
Furthermore, as shown in Table 4, when PAPP-A was 
combined with other factors, the AUC improved to 0.83 
(95% CI 0.75–0.91) in subjects with T2DM, 0.83 (95% CI 
0.77–0.89) in all subjects, and 0.80 (95% CI 0.70–0.90) in 


















T2DM ( ) (n=184)
T2DM (+) (n=136)
Fig. 2 Cardiovascular outcomes during 2 years post ACS. Kaplan–Meier estimated event‑free survival for the composite cardiovascular outcome 
(composite of cardiovascular death, non‑fatal myocardial infarction or non‑fatal ischemic stroke) in all ACS patients and patients with or without 
T2DM
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those without T2DM. None of these improvements in 
AUC was statistically significant compared to PAPP-A 
alone.
Discussion
Recurrent CV events post ACS in T2DM
Recurrent cardiovascular events in post ACS patients 
treated with current standard medical therapy and revas-
cularization interventions (PCI or CABG) remain an 
important clinical issue [25, 26]. A multinational study 
by the GRACE investigators [27] showed that CV death 
occurred in 4.1%, re-infarction in 4.4%, and stroke in 1.3% 
during 2 years of follow-up in 22,937 ACS patients from 
57 sites. Our study found 4.4% CV death, 9.0% nonfatal 
MI and 7.8% stroke during 24 months of post ACS. The 
higher recurrent event rates in our study could be asso-
ciated with a higher percentage of patients with T2DM 
(43%) compared to 25% in GRACE since other patient 
characteristics and ACS treatment were similar between 
our study and GRACE [27]. Indeed, we found a higher 
composite endpoint (CV death, nonfatal MI, stroke) rate 
during 24 months post ACS in the patients with T2DM 
Table 2 Univariate Cox regression analysis for cardiovascular outcome
HR hazard ratio, CI confidence interval, LVEF (%) percentage of LVEF >50%, other abbreviations as in Table 1
All (n = 320) T2DM (−) (n = 184) T2DM (+) (n = 136)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age, per 1SD 1.65 (1.26–2.17) <0.001 1.42 (0.94–2.15) 0.09 1.82 (1.25–2.63) 0.002
Male gender 1.45 (0.87–2.41) 0.2 0.69 (0.26–1.84) 0.5 1.85 (0.97–3.53) 0.06
BMI, per 1SD 0.84 (0.65–1.09) 0.2 0.82 (0.55–1.23) 0.3 0.84 (0.60–1.18) 0.3
Hypertension 2.04 (1.12–3.70) 0.02 2.75 (1.03–7.33) 0.04 1.47 (0.69–3.11) 0.3
Hyperlipidemia 0.81 (0.49–1.34) 0.4 0.76 (0.34–1.67) 0.5 0.74 (0.39–1.40) 0.4
Previous CAD 1.54 (0.90–2.64) 0.12 2.19 (0.98–4.88) 0.055 1.24 (0.59–2.64) 0.6
Previous stroke 1.07 (0.53–2.16) 0.9 1.62 (0.61–4.31) 0.3 0.74 (0.26–2.09) 0.6
LVEF (%), per 1SD 0.70 (0.55–0.88) 0.003 0.61 (0.43–0.86) 0.005 0.87 (0.63–1.20) 0.4
HbA1C, per 1SD 1.32 (1.06–1.63) 0.01 0.82 (0.51–1.31) 0.4 1.14 (0.82–1.57) 0.4
log10(TG), per 1SD 0.92 (0.72–1.19) 0.5 0.89 (0.60–1.33) 0.6 0.82 (0.58–1.15) 0.2
TC, per 1SD 0.87 (0.67–1.13) 0.3 0.94 (0.62–1.42) 0.8 0.80 (0.58–1.11) 0.2
HDL‑C, per 1SD 0.95 (0.73–1.23) 0.7 0.81 (0.52–1.27) 0.4 1.05 (0.77–1.44) 0.8
LDL‑C, per 1SD 0.88 (0.68–1.14) 0.3 1.06 (0.71–1.57) 0.8 0.77 (0.56–1.07) 0.12
GFR, per 1SD 0.60 (0.48–0.74) <0.001 0.65 (0.47–0.90) 0.008 0.57 (0.42–0.77) <0.001
CK‑MB, per 1SD 1.01 (0.79–1.31) 0.9 1.16 (0.86–1.57) 0.3 0.85 (0.56–1.31) 0.5
Troponin I, per 1SD 1.30 (1.10–1.54) 0.002 1.23 (0.92–1.66) 0.2 1.33 (1.10–1.62) 0.004
hsCRP, per 1SD 1.84 (1.43–2.37) <0.001 1.77 (1.20–2.60) 0.004 1.75 (1.25–2.46) 0.001
log10(PAPP‑A), per 1SD 3.10 (2.48–3.87) <0.001 3.16 (2.27–4.39) <0.001 2.97 (2.11–4.18) <0.001
Table 3 Unadjusted and adjusted effects of PAPP-A
HR for 1 SD increase in  log10 PAPP-A for single covariates. All adjusted HRs for PAPP-A are adjusted for the single variable that is specified
* p < 0.001 for all variables
** Percent change in HR compared to the unadjusted HR
All (n = 320) T2DM (−) (n = 184) T2DM (+) (n = 136)
HR (95% CI)* % Δ** (%) HR (95% CI)* % Δ** (%) HR (95% CI)* %Δ** (%)
Unadjusted 3.10 (2.48–3.87) 0 3.16 (2.27–4.39) 0 2.97 (2.11–4.18) 0
Adjusted for
 Age 2.93 (2.34–3.66) −5 3.04 (2.14–4.32) −4 3.16 (2.21–4.53) 6
 Sex 3.05 (2.44–3.82) −1 3.36 (2.36–4.79) 7 3.04 (2.14–4.31) 2
 LVEF (%) 3.02 (2.41–3.79) −3 2.96 (2.11–4.17) −6 2.97 (2.11–4.19) 0
 HbA1C 3.06 (2.43–3.86) −1 3.18 (2.23–4.55) 1 2.98 (2.11–4.19) 0
 Troponin I 3.09 (2.46–3.88) 0 3.18 (2.27–4.45) 1 2.89 (2.05–4.07) −3
 hsCRP 2.86 (2.21–3.69) −8 2.95 (2.02–4.30) −7 2.79 (1.88–4.13) −6
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than those without (27 vs. 13%), which is consistent with 
the accumulated evidence that diabetes increases the risk 
of recurrent cardiovascular events post ACS [28–30].
PAPP‑A forms and levels among populations
There are 2 forms of PAPP-A. During pregnancy, PAPP-A 
produced by placental syncytiotrophoblast cells is a het-
erotetrameric complex (500 kDa) covalently linked with 
eosinophil major basic protein [6]. This form is proteo-
lytically inactive. The distribution of PAPP-A was inves-
tigated in pregnant women and found that it varies by 
ethnicity, gestational age, maternal weight and smoking 
status [31–35]. The clinical investigations of the complex 
relationship among PAPP-A levels during pregnancy, ges-
tational diabetes (GDM) and cardiovascular disease risk 
are evolving [36–39]. Low levels of PAPP-A during the 
Fig. 3 Predictors of cardiovascular outcome 2 years post ACS. Receiver operating characteristics (ROC) curves for PAPP‑A and other factors predict‑
ing cardiovascular outcome 2 years post ACS in a patients with T2DM; b patients without T2DM; and c all patients. Specifically, in ACS patients with 
T2DM, area under the ROC curve (AUC) was 0.79 for PAPP‑A in brown color line, 0.69 for age in purple, 0.52 for LVEF in gold, 0.66 for GFR in blue, 0.64 
for hsCRP in red, and 0.83 for all 5 factors combined in black
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first trimester are associated with fetal Down’s syndrome 
[40] and other adverse events [37, 41–43]. A recent study 
[39] among Chinese women showed that PAPP-A levels 
in the first trimester were not predictive of development 
of GDM which is highly prevalent (approximately 19%) in 
China [44]. History of GDM in the 102 women (100 post-
menopause) enrolled in our study was not collected.
In contrast, the other form of PAPP-A secreted by vas-
cular cells [4, 7–10] is a homodimer (400 kDa) not cova-
lently linked with eosinophil major basic protein. This 
form has proteolytic activity [6] and is considered to play 
an important role in cardiovascular disease [45]. In gen-
eral, the concentration of PAPP-A is found to be very low 
in adult males and non-pregnant females [16]. In addi-
tion to the association of elevated PAPP-A levels with 
atherosclerotic vascular disease [11–14], recently, PAPP-
A was found to be a useful biomarker for cardiovascu-
lar dysfunction, inflammatory state and malnutrition 
in chronic kidney disease (CKD) patients undergoing 
hemodialysis [46]. Additionally, PAPP-A may be involved 
in the pathogenesis of retinal vein occlusion (RVD) [47] 
and the development of chronic obstructive pulmonary 
disease (COPD) [48].
PAPP-A was reported to be higher in T2DM than 
healthy controls in 2 studies [15, 16], appeared to be 
negatively associated with HbA1C levels [49], and its 
expression in glomeruli was associated with diabetic 
nephropathy [50]. Our study found significantly higher 
concentrations of PAPP-A in ACS patients with T2DM 
than those without (19 vs. 13  ng/ml, p  <  0.001). These 
results represent the increased inflammatory state in 
ACS and T2DM, particularly in ACS combined with 
T2DM [51] and is supported by previous investigations 
[9, 10, 13, 14]. These investigations have demonstrated 
that PAPP-A was produced and released by monocytes/
macrophages, was found in ruptured and eroded plaques 
and co-localized with vascular smooth muscle cells and 
activated macrophages, and was associated with higher 
3-vessel TCFA burden as assessed by virtual histology 
(VH)-intravascular ultrasound (IVUS) [14] and carotid 
plaque instability by Doppler ultrasonography in patients 
with acute ischemic stroke [52].
Prediction of PAPP‑A for recurrent CV events post ACS 
in T2DM
Previously, the MERLIN–TIMI-36 study investigators 
reported that PAPP-A was independently associated with 
recurrent cardiovascular events in patients with non-
STEMI ACS [53]. Our study found that PAPP-A was a 
significantly stronger predictor of 2-year recurrent events 
post ACS in all subjects and in T2DM. A larger AUC 
(0.79) was observed in comparison to other identified 
risk predictors (Table 2) including age (AUC 0.69), LVEF 
(AUC 0.52), eGFR (AUC 0.66) and hsCRP (AUC 0.64). 
Wlazeł and colleagues [54] examined the clinical value 
of PAPP-A in predicting future events post ACS and sug-
gested that a panel of 2–3 biomarkers (PAPP-A—hsCRP, 
PAPP-A—FBG, PAPP-A—hsCRP—FBG) can improve 
the risk prediction. In our study, when other risk predic-
tors were combined with PAPP-A, the AUC increased 
from 0.79 to 0.83 in T2DM, which was not a statistically 
significant improvement compared to the model with 
PAPP-A alone (Fig. 3; Table 4). However, the independ-
ent risk prediction of PAPP-A for future cardiovascular 
events post ACS in patients with T2MD needs to be con-
firmed in larger prospective population studies. Further-
more, other investigators suggested that the free PAPP-A 
was a stronger risk predictor of recurrent CV events 
1 year post-ACS when compared to total PAPP-A [55] as 
measured in our study. Future studies are also needed to 
confirm whether there is different clinical value between 
the free PAPP-A and total PAPP-A.
Limitations and future directions
Our study was performed in a very high-risk popula-
tion all with ACS and  >40% with T2DM, plus 40% of 
subjects with multiple risk factors including hyperten-
sion, hyperlipidemia and smoking. The sensitivity and 
Table 4 Area under the ROC curve (AUC) for PAPP-A, other selected factors and a multivariate model (all factors)
AUC areas under the receiver operating characteristics curve, Multivariate a multivariate logistic regression using all factors presented in this table, p value comparison 
to the PAPP-A model; Ref. reference
All (n = 320) T2DM (−) (n = 184) T2DM (+) (n = 136)
AUC (95% CI) p value AUC (95% CI) p value AUC (95% CI) p value
PAPP‑A 0.80 (0.74–0.87) Ref. 0.78 (0.67–0.88) Ref. 0.79 (0.70–0.87) Ref.
Diabetes 0.61 (0.54–0.67) <0.001
Age 0.65 (0.58–0.73) 0.003 0.60 (0.48–0.72) 0.051 0.69 (0.59–0.79) 0.15
LVEF (%) 0.60 (0.52–0.68) <0.001 0.66 (0.54–0.77) 0.06 0.52 (0.40–0.64) <0.001
eGFR 0.66 (0.58–0.74) <0.001 0.64 (0.52–0.76) 0.051 0.66 (0.56–0.77) 0.03
hsCRP 0.68 (0.60–0.75) 0.003 0.69 (0.57–0.80) 0.2 0.64 (0.52–0.76) 0.01
Multivariate (all above) 0.83 (0.77–0.89) 0.12 0.80 (0.70–0.90) 0.2 0.83 (0.75–0.91) 0.051
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specificity of PAPP-A as a strong predictor for CV events 
could be influenced by the selected high-risk population. 
In addition, this study was performed at a single center. 
Although a recent report by Conover and colleagues 
showed that inhibition of PAPP-A proteolytic activity 
by monoclonal antibody reduced atherosclerotic plaque 
progression in the apolipoprotein E knock-out mice [56] 
and a previous study showed that high dose of atorvas-
tatin was associated with PAPP-A reduction in patients 
with ACS [57], whether reduction of PAPP-A and by 
which therapeutic options can improve clinical outcomes 
remain unanswered.
Finally, the assay methods need to be standardized 
technically and the optimal cut-off levels for risk strati-
fication need to be defined clinically. Future research will 
be necessary to address these questions and to investi-
gate the biological role and therapeutic implications of 
PAPP-A.
In conclusion, PAPP-A, a novel plaque inflammatory 
marker, was significantly higher in ACS patients with 
T2DM than those without. It was found to be a stronger 
predictor for increased risk of future CV events 2 years 
post-ACS in patients with T2DM when compared to 
hsCRP and other factors.
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